key: cord-0722772-p1sxjf0e
authors: Benjamanukul, Saovanee; Traiyan, Sasiwimon; Yorsaeng, Ritthideach; Vichaiwattana, Preeyaporn; Sudhinaraset, Natthinee; Wanlapakorn, Nasamon; Poovorawan, Yong
title: Safety and immunogenicity of inactivated COVID‐19 vaccine in health care workers
date: 2021-11-24
journal: J Med Virol
DOI: 10.1002/jmv.27458
sha: e1aa363ed917855253726223ce45a82ea602717d
doc_id: 722772
cord_uid: p1sxjf0e

Effective vaccines are essential for controlling the coronavirus disease 2019 (COVID‐19) pandemic. CoronaVac, which is an inactivated virus vaccine, was the first imported COVID‐19 vaccine in Thailand. To investigate the safety and immunogenicity of CoronaVac within the Thai population, we conducted a prospective cohort study among health care workers aged 18–59 years, who received a 2‐dose regimen of CoronaVac 21 days apart between March and April 2021 at the hospital in Samut Sakhon, Thailand. We recruited 185 participants with a mean age of 32 years. Total antibodies against receptor‐binding domain (RBD) and immunoglobulin G (IgG) against nucleocapsid (N) protein of SARS‐CoV‐2 were tested. Total antibodies against RBD were negative before immunization. One volunteer was positive for N, although negative for the RBD antibodies. The seroconversion rate of total antibodies against RBD after the first CoronaVac dose was 67% with a Geometric mean concentration (GMC) of 1.98 U/ml. Following CoronaVac dose 2, the seroconversion rate increased to 100% with a GMC of 92.9 U/ml. The seroconversion rates of IgG against N protein were 1% after dose 1 and 62.8% after dose 2. The overall incidence of adverse reactions was 59.5%. Injection‐site pain was the most common local adverse event (52.4%), while myalgia was the most common systemic adverse event (31.9%). No serious adverse events were observed. A 0–21 days, 2‐dose CoronaVac regimen appears safe, inducing a satisfactory response compared with convalescent serum obtained 4–6 weeks postnatural infection. Antibody responses after 2‐dose CoronaVac were comparable to the convalescent plasma but waned rapidly after 3 months. Therefore, we recommend 2‐dose CoronaVac administration with possible booster doses.

Coronavirus disease 2019 is caused by the severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2), which spread rapidly, reaching pandemic status and presenting high morbidity and mortality in March 2020. 1 As of September 2021, SARS-CoV-2 has infected more than 230 million people worldwide, resulting in over 4 million deaths. 2 Moreover, COVID-19 has had adverse global impacts on education, 3 psychosocial well-being, 4 and economies. 5 Given the need for a robust and enduring immune response to fight with this virus, an effective vaccine is an essential strategy for controlling the COVID-19 pandemic. As of September 2021, there protein in the ribonucleoprotein core; and the spike (S) protein, matrix (M) protein, and envelope (E) protein embedded on the viral surface. 8 The S protein is the primary target antigen for COVID-19 vaccine development. Antibodies against the S protein, especially the receptor-binding domain (RBD) epitope, are essential for preventing the virus from entering target cells. Moreover, S protein has been identified as a significant inducer of protective immunity against SARS-CoV-2. N protein is highly immunogenic and induces a robust humoral and cellular immune response. 9, 10 Inactivated vaccines are whole virus preparations that are chemically-inactivated with beta-propiolactone and formaldehyde. 11 Although they are no longer replication-competent, virus integrity is preserved, serving as an immunogen that is S-specific, RBD-specific and N-specific. 8 Studies have shown that inactivated vaccines have favorable safety profiles in various populations and can induce antibody responses. 12, 13 CoronaVac, also known as the CoronaVac vaccine, is an inactivated vaccine against SARS-CoV-2 which is propagated in cell culture before being inactivated, concentrated, purified and adsorbed to aluminum hydroxide. CoronaVac is developed by Sinovac Life Sciences. 14 The results of a preclinical study showed that CoronaVac effectively induced neutralizing antibody and T cell responses in animals and provided partial or complete protection in macaques following a SARS-CoV-2 challenge. 15 However, inactivated vaccines are whole virus preparations that can induce non-neutralizing antibodies, which might contribute to antibodydependent enhancement and disease severity. 16 Nonetheless, some studies have failed to find evidence of antibody-dependent enhancement in animal models after CoronaVac. 15 Safety and immunogenicity profiles in phase 1/2 trials showed that this vaccine was well-tolerated and induced a moderate immunogenic response in healthy adults. 12 Randomized controlled trials of CoronaVac in a phase III study showed efficacy 83.5% against symptomatic disease with a good safety profile. 17 However, many issues regarding vaccine performance remain unclear, including vaccination dosing intervals that differ from those used in the original trial and the duration of protection in real-world conditions. Longitudinal studies are thus required to determine the duration of protective immunity.

In Thailand, CoronaVac, which was the first vaccine imported for controlling the COVID-19 outbreak, was approved for emergency use in February 2021, 18 

The participants, who were health care workers (HCWs) at BGH aged between 18 and 59 years, received a 2-dose regimen of CoronaVac, with a 3-week interval between doses (0-21-day schedule). The study's exclusion criteria were a previous diagnosis of SARS-CoV-2 infection, a known allergy to any vaccine components, underlying allergic diseases, a diagnosis of an immunocompromising or immunodeficiency disorder, treatment with immunosuppressive therapy, cancer, or an uncontrolled chronic medical condition. Participants who were pregnant or breastfeeding were also excluded from this study.

Participants' demographic data, namely their age, sex, occupation, and comorbidities were recorded. Moreover, we measured baseline antibodies against RBD and N protein immediately before vaccination in all of the enrolled participants to determine baseline SARS-CoV-2 serostatus. Assessments of the immunogenicity of CoronaVac, total antibodies against RBD, and Immunoglobulin G (IgG) antibodies against N protein, which were primary study outcomes, were performed 3 weeks after dose 1, and 1 and 3 months after dose 2 ( Figure 1 ). Levels of antibodies obtained using samples of convalescent serum collected 4-6 weeks after a natural infection from infected COVID-19 patients of the previous study 19 were measured and concentrations of antibodies were compared with those obtained from the vaccine-induced immune response. The secondary outcome comprised assessments of local adverse reactions to the vaccine (e.g., pain, swelling, and redness) or systemic adverse events (e.g., fever, allergic reactions, headaches, and myalgia) recorded by the participants over a 7-day period after each vaccination. 

Serum samples from all of the participants were tested for total antibodies against RBD. Measurements of total antibodies (predominantly IgG, but also IgA and IgM) against the RBD were obtained from electrochemiluminescence immunoassay, Roche Elecsys Anti-SARS-CoV-2 S (Cat. No. 09289267190; Roche). These kits used a Wild-type or Wuhan strain as an antigen. The positive cut-off level was ≥0.80 U/ ml and the upper limit was 250 U/ml. If the total antibodies against RBD exceeded the upper reading limit (250 U/ml), serum samples were diluted to obtain values within a detectable range. 

We calculated a sample size of 75 individuals based on 95% Cor-onaVac seroconversions obtained in a previous study. 20 Statistical analysis was performed using GraphPad Prism (version 9.1.0). Correlation between age and total antibodies against RBD and IgG against N protein were assessed with Spearman's rank correlation coefficient. The seroconversion rates of total antibodies against RBD and IgG against N protein were calculated as percentages. We cal- (Table 1) . Two participants dropped out of the study before the third blood sampling stage; one was pregnant and the other was 

The overall incidence of adverse reactions to the CoronaVac vaccines was 59.5%. Local adverse events occurred more frequently than sys- We found that 2 CoronaVac doses administered 3 weeks apart were safe and induced a satisfactory response. This CoronaVac regimen induced immunization against RBD comparable to levels However, the declines in the seroconversion rate and in the level of IgG antibodies against N protein in our study 3 months postvaccination were greater than that of antibodies against RBD, which is consistent with the findings of a previous study. 31, 35 This result may be attributed to the lower half-life of nucleocapsid antibodies compared with that of antibodies against RBD in natural infection. 36 Thus, antibody response may temporarily increase and then decline over time, and booster vaccines may be required.

There are some limitations in our study. Our examination of immunogenicity was confined to humoral immunity and did not include cellular mediated immunity. Additionally, the neutralizing These data may not be generalizable to individuals with comorbidities or allergies. Nevertheless, we hope that our findings will inform future vaccination policies or strategies to control the COVID-19 pandemic.

We are grateful to Dr. Patcharee Kiatsermsakul, who facilitated data collection and to Miss Sirinthip Nimitphuwadon and Miss Jantakan Leauchom, the nurses and all participating staff at Banphaeo General Hospital who assisted in this project. We thank the National Research

Council of Thailand (NRCT) and Center of Excellence in Clinical Virology, Chulalongkorn University and King Chulalongkorn Memorial

Hospital for supporting this study.

The authors declare that there are no conflict of interests. 

The supporting data are available within the article.

Yong Poovorawan http://orcid.org/0000-0002-2337-6807

High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2

World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2021

The impact of the COVID-19 pandemic on medical education

Emotional, behavioral, and psychological impact of the COVID-19 pandemic

Observed impacts of the COVID-19 pandemic on global trade

World Health Organization. Draft landscape of COVID-19 candidate vaccines

World Health Organization. COVID-19 advice for the public: Getting vaccinated

Viral targets for vaccines against COVID-19

Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages

Approaches and challenges in SARS-CoV-2 vaccine development

Overview of approved and upcoming vaccines for SARS-CoV-2: a living review

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial

World Health Organization. Covid-19 vero cell inactivated

Development of an inactivated vaccine candidate for SARS-CoV-2

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Food and Drug Administration, Ministry of Public Health, Thailand. Details of Medicinal Product

Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets

Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a singleblind, randomised, controlled, phase 2/3 trial

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status

Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers

Correlates of protection against SARS-CoV-2 in rhesus macaques

Antibody status and incidence of SARS-CoV-2 infection in health care workers

Evidence for antibody as a protective correlate for COVID-19 vaccines

Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

Antibody response to SARS-CoV-2 infection in humans: a systematic review

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19

Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers